Understanding the impact of constraints: A rank based fitness function for evolutionary methods

There are design problems where some constraints may be considered objectives as in “It would be great if the solution we obtained had this characteristic.” In such problems, solutions obtained using multi-objective optimisation may help the decision maker gain insight into what is achievable without fully satisfying one of these constraints. A novel fitness function is introduced into a multi-objective population based evolutionary optimisation method, based on a plant propagation algorithm extended to multi-objective optimisation. The optimisation method is implemented and applied to the design of off-grid integrated energy systems for large scale mining operations where the aim is to use local renewable energy generation, coupled with energy storage, to eliminate the need for transporting fuel over large distances. The latter is a desired property and in this chapter is treated as a separate objective. The results presented show that the fitness function provides the desired selection pressure and, when combined with the multi-objective plant propagation algorithm, is able to find good designs that achieve the desired constraint simultaneously

Properties of Nucleon Resonances by means of a Genetic Algorithm

We present an optimization scheme that employs a Genetic Algorithm (GA) to determine the properties of low-lying nucleon excitations within a realistic photo-pion production model based upon an effective Lagrangian. We show that with this modern optimization technique it is possible to reliably assess the parameters of the resonances and the associated error bars as well as to identify weaknesses in the models. To illustrate the problems the optimization process may encounter, we provide results obtained for the nucleon resonances $\Delta$(1230) and $\Delta$(1700). The former can be easily isolated and thus has been studied in depth, while the latter is not as well known experimentally.Comment: 12 pages, 10 figures, 3 tables. Minor correction

Constant-time solution to the Global Optimization Problem using Bruschweiler's ensemble search algorithm

A constant-time solution of the continuous Global Optimization Problem (GOP) is obtained by using an ensemble algorithm. We show that under certain assumptions, the solution can be guaranteed by mapping the GOP onto a discrete unsorted search problem, whereupon Bruschweiler's ensemble search algorithm is applied. For adequate sensitivities of the measurement technique, the query complexity of the ensemble search algorithm depends linearly on the size of the function's domain. Advantages and limitations of an eventual NMR implementation are discussed.Comment: 14 pages, 0 figure

Country-specific birth weight and length in type 1 diabetes high-risk HLA genotypes in combination with prenatal characteristics

Objective:To examine the relationship between high-risk human leukocyte antigen (HLA) genotypes for type 1 diabetes and birth size in combination with prenatal characteristics in different countries.Study Design:Four high-risk HLA genotypes were enrolled in the Environmental determinants of Diabetes in the Young study newborn babies from the general population in Finland, Germany, Sweden and the United States. Stepwise regression analyses were used to adjust for country, parental physical characteristics and environmental factors during pregnancy.Result:Regression analyses did not reveal differences in birth size between the four type 1 diabetes high-risk HLA genotypes. Compared with DQ 4/8 in each country, (1) DQ 2/2 children were heavier in the United States (P=0.028) mostly explained however, by parental weight; (2) DQ 2/8 (P=0.023) and DQ 8/8 (P=0.046) children were longer in Sweden independent of parents height and as well as (3) in the United States for DQ 2/8 (P=0.023), but again dependent on parental height.Conclusion:Children born with type 1 diabetes high-risk HLA genotypes have comparable birth size. Longitudinal follow-up of these children should reveal whether birth size differences between countries contribute to the risk for islet autoimmunity and type 1 diabetes.Journal of Perinatology advance online publication, 28 April 2011; doi:10.1038/jp.2011.26

HLA Genes, Islet Autoantibodies and Residual C-Peptide at the Clinical Onset of Type 1 Diabetes Mellitus and the Risk of Retinopathy 15 Years Later

HLA genes, islet autoantibodies and residual C-peptide were studied to determine the independent association of each exposure with diabetic retinopathy (DR), 15 years after the clinical onset of type 1 diabetes in 15-34 year old individuals.The cohort was identified in 1992 and 1993 by the Diabetes Incidence Study in Sweden (DISS), which investigates incident cases of diabetes for patients between 15 and 34 years of age. Blood samples at diagnosis were analyzed to determine HLA genotype, islet autoantibodies and serum C-peptide. In 2009, fundus photographs were obtained from patient records. Study measures were supplemented with data from the Swedish National Diabetes Registry.The prevalence of DR was 60.2% (148/246). Autoantibodies against the 65 kD isoform of glutamate decarboxylase (GADA) at the onset of clinical diabetes increased the risk of DR 15 years later, relative risk 1.12 for each 100 WHO units/ml, [95% CI 1.02 to 1.23]. This equates to risk estimates of 1.27, [95% CI 1.04 to 1.62] and 1.43, [95% CI 1.06 to 1.94] for participants in the highest 25(th) (GADA>233 WHO units/ml) and 5(th) percentile (GADA>319 WHO units/ml) of GADA, respectively. These were adjusted for duration of diabetes, HbA(1c), treated hypertension, sex, age at diagnosis, HLA and C-peptide. Islet cell autoantibodies, insulinoma-antigen 2 autoantibodies, residual C-peptide and the type 1 diabetes associated haplotypes DQ2, DQ8 and DQ6 were not associated with DR.Increased levels of GADA at the onset of type 1 diabetes were associated with DR 15 years later. These results, if confirmed, could provide additional insights into the pathogenesis of the most common microvascular complication of diabetes and lead to better risk stratification for both patient screenings and DR treatment trials